Blood thinners increase perioperative complication risk

Article

Use of warfarin or clopidogrel is associated with a significant increase in non-sight-threatening complications during cataract surgery, concluded a study published in the January issue of Eye.

Use of warfarin or clopidogrel is associated with a significant increase in non-sight-threatening complications during cataract surgery, concluded a study published in the January issue of Eye.

Rob L. Johnston, of the Gloucestershire Eye Department, Cheltenham General Hospital, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, Gloucestershire, UK and colleagues remotely used the Cataract National Dataset to extract and analyse data on 48,862 operations for which other pharmaceutical information was available, and assessed how these drugs impacted complication rates. The operations assessed were conducted across eight National Health Service (NHS) centres between 2001 and 2006; 28.1% of the patients studied were taking aspirin, 5.1% were taking warfarin, 1.9% were taking clopidogrel and 1.0% were taking dipyridamole.

The data showed that 8.0% of clopidogrel users reported sharp needle or subtenon’s cannula local anaesthetic block. This compares with 6.2% of warfarin users and 4.3% of other patients. The incidence of sight-threatening complications, however, was similar across all groups. The incidence of subconjunctival haemorrhage was 4.4% for clopidogrel users, 3.7% for warfarin users and 1.7% of other patients. Posterior capsular rupture (PCR) incidence was 3.23% in clopidogrel users and 1.77% for other patients. Overall, 7.3% of clopidogrel users experienced a perioperative complication, compared with 4.4% of other patients.

The researchers concluded that use of either clopidogrel or warfarin increased the likelihood of sharp needle or subtenon’s cannula during cataract surgery, although the risk of sight-threatening or haemorrhagic complications was not increased.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.